ClinicalTrials.gg
RecruitingNCT07192055SOLOUpdated May 12, 2026

Self-sampling to Optimize Anal Lesion Outcomes

An interventional study of Self-sampling and Nylon-flocked Swab in Anal Cancer, sponsored by Medical College of Wisconsin. Recruiting at 3 sites in United States. Open to participants aged 35 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
572
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Study summary

The purpose of this research study is to find ways to increase anal cancer screening among people at increased risk for anal cancer. This study will try to find out if persons will do an intervention (self-sampling of the anal canal) and if it affects cytology and high-resolution anoscopy (HRA) appointment attendance. Secondarily, the study will assess if a person who gets their choice of either self-sampling or healthcare provider sampling affects clinic attendance.

02

Conditions studied

  • Anal Cancer

Browse trials for

Keywords

  • anal cancer
  • human papillomavirus
03

In context

Anus Neoplasms

297 studies on the registry are indexed under Anus Neoplasms; 74 are open to participants now.

This study's planned enrollment of 572 is above the median of 66 across 211 interventional studies indexed under Anus Neoplasms.

Browse Anus Neoplasms studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 548 studies on the registry; 122 are open to participants now.

Of its 75 completed or terminated interventional studies of FDA-regulated products, 57 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

A potential study subject who meets all of the following inclusion criteria is eligible to participate in the study. Note that these criteria apply regardless of HPV vaccination status or disability status.

Inclusion criteria

Inclusion Criteria:

  1. Age ≥ 35 years for those who are -positive or ≥ 45 years for those who are HIV-negative.
  2. Must be either:

    1. A cisgender or transgender sexual minority man, or
    2. A transgender woman who has sex with men.
  3. Resides in Chicago, Houston, or Milwaukee metropolitan area.
  4. Is willing to attend a study clinic.
  5. Speak and understand either English or Spanish
  6. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

A potential study subject who meets any of the following exclusion criteria is ineligible to participate in the study.

  1. Was a participant in the PAC Self-Swab Study in Milwaukee.
  2. Currently on anticoagulants, with the exception of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), e.g., ibuprofen, naproxen.
  3. Diagnosed with hemophilia, cirrhosis with bleeding varices, or thrombocytopenia.
  4. Presence of any contraindicating severe disease or condition, e.g., anal stenosis.
  5. Plans to move within 12 months after enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
572 participants (estimated)

Study arms

  • Experimental
    Self-sampling

    Participants will self-sample the anal canal with a swab. They will do this at home and at a clinic.

    Other: Nylon-flocked Swab

  • Active comparator
    Clinician sampling

    A clinician will collect a sample from the anal canal of the participant with a swab. They will do this at the clinic.

    Behavioral: Self-sampling · Other: Nylon-flocked Swab

  • Experimental
    Nylon-flocked swab

    This is a swab with nylon-flocked material at the tip.

    Behavioral: Self-sampling

  • Active comparator
    Dacron swab

    This is a swab with a Dacron tip.

    Behavioral: Self-sampling · Other: Nylon-flocked Swab

Interventions

  • BehavioralSelf-sampling

    Self-sampling instructions will be provided to participants who will insert the swab into the anus to collect cells. Then the participant will put the swab in a vial of transport fluid for assessment at a laboratory.

    Also known as: self-collection

  • OtherNylon-flocked Swab

    At the cytology appointment, participants may receive self-sampling or clinician sampling with 1 of 2 kinds of swabs. The nylon-flocked swab is the intervention and will be assessed on patient acceptability and patient and clinician ability to collect an adequate sample.

06

What researchers measure

Primary outcomes

  1. Effect of the self-sampling intervention at cytology

    Determine the number of individuals who attend the cytology appointment after exposure to the self-sampling intervention.

    Time frame: 1 month

  2. Effect of self-sampling intervention at high-resolution anoscopy

    Determine the number of individuals who attend the high-resolution anoscopy appointment after exposure to the self-sampling intervention.

    Time frame: 2 months

Secondary outcomes

  1. Effect of the self-sampling intervention at cytology on people with human immunodeficiency virus (HIV)

    Determine the number of individuals with HIV who attend the cytology appointment after exposure to the self-sampling intervention.

    Time frame: 1 month

  2. Effect of the self-sampling intervention at high-resolution anoscopy on people with HIV

    Determine the number of individuals with HIV who attend the high-resolution anoscopy appointment after exposure to the self-sampling intervention.

    Time frame: 2 months

  3. Effect of the self-sampling intervention at cytology on people randomized to their preferred sampling method

    Assess the number of participants who attend their cytology appointment in the group randomized to their preferred sampling method.

    Time frame: 1 month

  4. Effect of the self-sampling intervention at high-resolution anoscopy on people randomized to their preferred sampling method

    Assess the number of participants who attend their high-resolution anoscopy appointment in the group randomized to their preferred sampling method.

    Time frame: 2 months

Other outcomes

  1. Effect of the self-sampling intervention among Black individuals at cytology

    Determine the number of Black individuals who attend the cytology appointment after exposure to the self-sampling intervention.

    Time frame: 1 month

  2. Effect of the self-sampling intervention among Black individuals at high-resolution anoscopy

    Determine the number of Black individuals who attend high-resolution anoscopy appointments after exposure to the self-sampling intervention.

    Time frame: 2 months

  3. Assess the adequacy of nylon-flocked swabs

    Determine the number of nylon-flocked swabs that are cytologically adequate (defined as 2000-3000 nucleated squamous cells/mm3).

    Time frame: 1 month

  4. Assess the adequacy of Dacron swabs

    Determine the number of Dacron swabs that are cytologically adequate (defined as 2000-3000 nucleated squamous cells/mm3).

    Time frame: 1 month

  5. Assess participant pain after using the nylon-flocked swab

    The Wong-Baker FACES® Pain Rating Scale measures the severity of pain, if any. Possible scores range from 0 to 10 with higher scores indicating increased severity of pain.

    Time frame: 1 month

  6. Assess participant pain after using the Dacron swab

    The Wong-Baker FACES® Pain Rating Scale measures the severity of pain, if any. Possible scores range from 0 to 10 with higher scores indicating increased severity of pain.

    Time frame: 1 month

  7. Assess participant comfort after using the nylon-flocked swab

    The variable comfort measures the individual's reported comfort on a 4-point Likert scale from Strongly Agree to Strongly Disagree. Possible scores range from 1 to 4 with higher scores indicating decreased comfort after using the nylon-flocked swab.

    Time frame: 1 month

  8. Assess participant comfort after using the Dacron swab

    The variable comfort measures the individual's reported comfort on a 4-point Likert scale from Strongly Agree to Strongly Disagree. Possible scores range from 1 to 4 with higher scores indicating decreased comfort after using the Dacron swab

    Time frame: 1 month

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Fully de-identified datasets will be shared with properly trained investigators after assessment of institutional policies, Medical College of Wisconsin Human Protections Committee rules, as well as local, state, and Federal laws and regulations.

Time frame: Data will become available one year after study completion.

Access criteria: Fully de-identified datasets will be shared with properly trained investigators after assessment of institutional policies, Medical College of Wisconsin Human Protections Committee rules, as well as local, state, and Federal laws and regulations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192055
Responsible party
Alan Nyitray, PhD (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Sep 25, 2025
Start date
Nov 18, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
May 12, 2026

Study contacts

Alan G Nyitray, PhD
Contact
anyitray@mcw.edu
4149557701
Jenna Nitkowski, PhD
Contact
jnitkowski@mcw.edu
414-955-2126
Alan Nyitray, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion